These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

991 related items for PubMed ID: 26681527

  • 1. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
    Wong IT, Shojania K, Dutz J, Tsao NW.
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN.
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [Abstract] [Full Text] [Related]

  • 3. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP.
    Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A.
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [Abstract] [Full Text] [Related]

  • 5. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT, Wolff RF, Pouwels X, Oosterhoff M, Van Giessen A, Worthy G, Noake C, Armstrong N, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [Abstract] [Full Text] [Related]

  • 6. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S, Foster SA, Burge R, Amato D, Schacht A, Zhu B, Hartz S, Leonardi C.
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [Abstract] [Full Text] [Related]

  • 7. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
    Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, Guerin A.
    J Dermatolog Treat; 2018 Feb; 29(1):24-31. PubMed ID: 28608740
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J.
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [Abstract] [Full Text] [Related]

  • 10. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.
    Egeberg A, Iversen L, Gniadecki R, Hvid L, Dam TN, Bryld LE, Skov L.
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1183-1187. PubMed ID: 28273375
    [Abstract] [Full Text] [Related]

  • 11. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
    Blauvelt A, Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S.
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ustekinumab for the treatment of moderate to severe psoriasis.
    Gospodarevskaya E, Picot J, Cooper K, Loveman E, Takeda A.
    Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety of secukinumab in the treatment of psoriasis.
    Blauvelt A.
    Expert Opin Drug Saf; 2016 Oct; 15(10):1413-20. PubMed ID: 27545070
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.